High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines

CNS Neuroscience and Therapeutics

Volumn 19, Issue 5, 2013, Pages 294-301

  Cummings, Jeffrey L ^a   Geldmacher, David ^b   Farlow, Martin ^c   Sabbagh, Marwan ^d   Christensen, Daniel ^e   Betz, Peter ^f  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SUN HEALTH RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f Piedmont Eye Center   (United States)

Author keywords

Alzheimer's disease; Donepezil; Efficacy; Moderate to severe; Safety; Tolerability

Indexed keywords

DONEPEZIL; MEMANTINE; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COGNITION; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEVER; HUMAN; NAUSEA; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; PATIENT SELECTION;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDANS; PATIENT SELECTION; PIPERIDINES; PRACTICE GUIDELINES AS TOPIC;

EID: 84876789305     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12076     Document Type: Review

References (43)

1. Alzheimer's Association. 2011 Alzheimer's disease facts and figures. Alzheimer's Association, 2011. Available at: http://www.alz.org/downloads/facts_figures_2011.pdf. Accessed October 29, 2012.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-1122.
3. Bergvall N, Brinck P, Eek D, et al. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease. Int Psychogeriatr 2011;23:73-85.
4. Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry 2010;18:917-927.
5. Gaugler JE, Yu F, Krichbaum K, Wyman JF. Predictors of nursing home admission for persons with dementia. Med Care 2009;47:191-198.
6. Gustavsson A, Brinck P, Bergvall N, et al. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. Alzheimers Dement 2011;7:318-327.
7. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51:737-744.
8. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537-545.
9. Herrmann N, Cappell J, Eryavec GM, Lanctot KL. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. CNS Drugs 2011;25:425-433.
10. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-944.
11. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-314.
12. Cappell J, Herrmann N, Cornish S, Lanctot KL. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. CNS Drugs 2010;24:909-927.
13. Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 2004;63:644-650.
14. Wimo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003;15:44-54.
15. Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003;21:327-340.
16. Exelon [US prescribing information]. East Hanover, NJ: Novartis Inc.; 2006. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf.
17. Exelon Patch [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf.
18. Razadyne and Razadyne ER [US prescribing information]. Titusville, NJ: Ortho McNeil Neurologics; 2011. Available at: http://www.razadyneer.com/sites/default/files/shared/pi/razadyne_er.pdf#zoom=100.
19. Namenda [US prescribing information]. St. Louis, MO: Forest Laboratories, Inc.; 2007. Available at: http://www.frx.com/pi/namenda_pi.pdf.
20. Aricept [US prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; 2010. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=510.
21. Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011;7:102-111.
22. Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010;9:749-751.
23. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-2564.
24. Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer's disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol 2011;11:21.
25. Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging 2008;25:163-174.
26. Brand-Schieber E, Zou H, Zhu W, et al. Long-term cognitive effect of increasing donepezil dose from 10 mg to 23 mg in moderate to severe Alzheimer's disease - impact of treatment delay. Presented at: 63rd Annual Meeting of the American Academy of Neurology (AAN); April 9-16, 2011; Honolulu, HI.
27. Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord 2012;33:164-173.
28. Farlow M, Veloso F, Moline M, et al. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol 2011;11:57.
29. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010;32:1234-1251.
30. Ferris SH, Schmitt FA, Saxton J, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimers Res Ther 2011;3:22.
31. Salloway S, Ramos H, Faison W, Zou H. Efficacy and safety of donepezil 23 mg/d versus donepezil 10 mg/d in moderate to severe Alzheimer's disease: subgroup analysis of US participants in a global study. Presented at: 63rd Annual Meeting of the American Academy of Neurology (AAN); April 9-16, 2011; Honolulu, HI.
32. Tariot P, Salloway S, Yardley J, Mackell J, Moline M. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. BMC Res Notes 2012;5:283.
33. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.
34. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-1065.
35. Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin 2004;20:1605-1612.
36. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:806-812.
37. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-433.
38. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004;11:734-741.
39. Saxton J, McGonigle-Gibson KL, Swihart AA, Miller VJ, Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess 1990;2:298-303.
40. Schmitt FA, Ashford W, Ernesto C, et al. The Severe Impairment Battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S51-S56.
41. Schmitt FA, Cragar D, Ashford JW, et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl 2002;62:135-148.
42. Schmitt FA, Mackell J, Richardson S, Xu Y. Evaluating cognitive benefits in patients with moderate to severe Alzheimer's disease treated with donepezil 23 mg/d: utility of the SIB-8 scale. Presented at: The 63rd Annual Meeting of the American Academy of Neurology (AAN); April 9-16, 2011; Honolulu, HI.
43. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:893-903.